What predicts non-retention in microbicide trials?

dc.contributor.authorFeldblum, P.J.
dc.contributor.authorHalpern, V.
dc.contributor.authorLie, C.C.
dc.contributor.authorObunge, O.
dc.contributor.authorOgunsola, F.
dc.contributor.authorAmpofo, W.
dc.contributor.authorOpoku, K.
dc.date.accessioned2019-05-08T08:41:27Z
dc.date.available2019-05-08T08:41:27Z
dc.date.issued2011-03
dc.description.abstractBackground: Poor retention can reduce study power and thwart randomization, possibly resulting in biased estimates of effect. Some HIV prevention trials conducted in developing countries have been challenged by high loss to follow-up. Identifying factors associated with non-retention could lead to recruitment of women more likely to remain in the trial, potentially yielding greater efficiency and validity. Methods: We summarized retention rates and, using Cox regression, evaluated factors associated with non-retention in four trials of two candidate vaginal microbicides (1% C31G or SAVVY® and 6% cellulose sulfate or CS) conducted in multiple sub-Saharan African countries. We defined retention as completion of the trial, including those with an HIV outcome. Non-retention comprised participants randomized to a study arm who were either lost to follow-up or discontinued prior to infection with HIV. Results: 7367 women were enrolled and randomized in the four trials; 7086 are included in this analysis. 1514 (21.4%) participants were either lost to follow-up or had early discontinuation. In the final Cox model, the following baseline factors were associated with non-retention: younger age (hazard ratio [HR] = 0.95); less education (HR = 0.97); condom use at last sex (HR = 1.18); larger number of sex acts in a typical week (HR = 1.01); and baseline candidiasis or bacterial vaginosis (HR = 1.12). Conclusions: Younger and less educated women were more difficult to retain in these microbicide trials. But these same traits may be associated with higher HIV infection rates. Enhanced retention methods focused on those at highest risk of non-retention and possibly infection will optimize study efficiency and validity. © 2011 Elsevier Inc.en_US
dc.identifier.otherVol.32(4): pp 512-6
dc.identifier.otherDOI: 10.1016/j.cct.2011.03.008
dc.identifier.urihttp://ugspace.ug.edu.gh/handle/123456789/29854
dc.language.isoenen_US
dc.publisherContemporary Clinical Trialsen_US
dc.subjectHIV preventionen_US
dc.subjectLoss to follow-upen_US
dc.subjectMicrobicidesen_US
dc.subjectProportional hazards modelingen_US
dc.subjectRandomized controlled trialsen_US
dc.subjectRetentionen_US
dc.titleWhat predicts non-retention in microbicide trials?en_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.6 KB
Format:
Item-specific license agreed upon to submission
Description: